LUCIUS 卢修斯 瑞戈非尼 Regorafenib结直肠癌

瑞戈非尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Regorafenib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Compositien:
Each film-coated tablet contains Regorafenib

结直肠癌

monohydrate 41 40 mo eauival

LUCiUS

udc +1.4 mg cquivalent to

PHARMACEUTICALS

Indicatio

.................. 40mg.
LuciRegor is a kinase inhibitor indicated for the
treatment of patients with metastatic colorectal

Rx Only

cancer(CRC) who have been previously treat
with fluoropyrimidine-, oxaliplatin-and

LuciRegor

notecan-based chemotherapy, an anti-VEGF
theraoy, and, if KRAS wild type, an anti-EGF
Dosage and Use:

Regorafenib Tablets

FDA批准

ntcommended Dose: 160 ig orally, once daily
for the first 21 days of cach 28-day eycle. Take

40mg

LuciRegor with food (a low-fat breakfast).
Storage: in a dry place and store at 20°℃ to 25°C.

Warming

Keep medicine out of reach of CHildren. Do nol
administer LuciRegor during Pregnancy and
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by:

LUCIUS

权威认证

Thongmang village, Xaythany distric
Vientiane Carital Laos
Warning : To be sold by retad on nreserie

by the phue only, and as directed

28 Tablets

口碑质量。

适应症:
适用于治疗转移性结直肠癌(CRC)患者,这些患者先前

曾接受过氟嘧啶、奥沙利铂和伊立替康为基础的化疗,抗
VEGF治疗,以及(如果是KRAS野生型)抗EGFR治疗。
推荐剂量:
·每28天周期的前21天,每日口服一次,每次160毫克。
·随餐服用(低脂早餐)。